In a goat study, the peptide Ovagen was tested against a commercial super‑ovulation drug (Folltropin). Both treatments produced about the same number of ovulated follicles and embryos, and Ovagen showed a slightly higher number of good-quality embryos, though the differences weren’t statistically significant. Ovagen also had fewer abnormal ovarian structures compared to Folltropin.

The purpose of the present study was to examine ovulation rates and embryo numbers and quality in goats of feral origin following treatment with either Folltropin (Vetrepharm Inc., Ontario, Canada) or Ovagen (Immuno-Chemical Products Ltd., Auckland). The mean +/- s.e.m. numbers of corpora lutea (CL) and embryos recovered after Ovagen treatment (N = 17 animals) were 16.2 +/- 2.1 and 12.6 +/- 1.9 respectively whereas after Folltropin treatment (N = 18 animals), the respective numbers were 16.3 +/- 1.8 and 10.2 +/- 1.6. The mean +/- s.e.m. numbers of good (i.e. transferable) embryos were 11.1 +/- 1.8 in the Ovagen group and 7.9 +/- 1.4 in the Folltropin group. AII the above values for each of the treatment groups were not significantly different from one another. There was a significant linear relationship between the number of CL and number of embryos (p<0.01; R = 0.925) after Ovagen treatment whereas there was no significant relationship after FolItropin treatment (p>0.05; R = 0.461). The proportions of animals producing more than five recoverable embryos after Ovagen (i.e. 76%) or Folltropin treatment (i.e. 72%) were similar although 22% of the Folltropin treated animals produced abnormal or prematurely regressing CL whereas no such CL were found after Ovagen treatment.